Arrowhead Pharmaceuticals (ARWR): COO sold ~$21K
Patrick O'brien, COO at Arrowhead Pharmaceuticals, sold ~$21K of Arrowhead Pharmaceuticals shares.
- ~$21K
- Approx. value · 313 sh @ $68.00
- 485K
- Holds after · shares reported
- Traded
- Jan 5, 2026
- Filed
- Jan 6, 2026
What stands out in this filing
- The sale was 0.1% of the shares this insider held before it; the filing reports 484,663 shares afterwards.
- 313 shares at an average of $68.00 each, as reported on the form.
- Footnote references a pre-arranged trading plan (Rule 10b5-1).
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
The company's last weighty Form 8-K report up to this date: reported its results, 41 days earlier (Nov 25, 2025). The first one after it: signed an important agreement, 2 days later (Jan 7, 2026).
- Company filing · Form 8-K · ResultsReported its results
- InsiderDirector sold ~$493K of ARWR shares in the open market
- InsiderDirector sold ~$992K of ARWR shares in the open market
- Insider · 1 personInsiders: 3 sales (~$9.0M)
- Insider · 1 personInsiders: 9 sales (~$3.4M)
- Insider · 1 personInsiders: 4 sales (~$5.4M)
- Insider · 4 peopleInsiders: 12 sales (~$2.8M)
- Insider · 1 personInsiders: 2 sales (~$861K)
- InsiderDirector sold ~$527K of ARWR shares in the open market
- Insider · 1 personInsiders: 2 sales (~$3.6M)
- Insider · 1 personInsiders: 2 sales (~$872K)
- InsiderOfficer sold ~$21K of ARWR shares in the open market
What came next
- Insider · 2 peopleInsiders: 18 sales (~$5.6M)
- Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
- Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
- Company filing · Form 8-K · ResultsReported its results
- InsiderOfficer sold ~$642K of ARWR shares in the open market
- Insider · 1 personInsiders: 3 sales (~$934K)
- InsiderOfficer sold ~$750K of ARWR shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Arrowhead Pharmaceuticals
OQRO holds no insider, Congress, fund or contract record for Arrowhead Pharmaceuticals dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ARWR page.
Other recent filings by Patrick O'brien, COO
- SEC Form 4 at Arrowhead Pharmaceuticals (ARWR)Jan 6, 2026
- SEC Form 4 at Arrowhead Pharmaceuticals (ARWR)Jan 6, 2026
- SEC Form 4 at Arrowhead Pharmaceuticals (ARWR)Jan 6, 2026
- SEC Form 4 at Arrowhead Pharmaceuticals (ARWR)Jan 6, 2026
- SEC Form 4 at Arrowhead Pharmaceuticals (ARWR)Jan 6, 2026
The full history of Patrick O'brien, COO is on the profile page.
How this filing works
Explore the data
Common questions
Which Arrowhead Pharmaceuticals (ARWR) insider traded, and how much?
Patrick O'brien, COO at Arrowhead Pharmaceuticals, sold ~$21K of Arrowhead Pharmaceuticals shares. 313 shares at $68.00.
When did it happen, and when was it made public?
Traded: Jan 5, 2026. Filed: Jan 6, 2026. That is 1 day between the two dates.
What stands out in this filing?
The sale was 0.1% of the shares this insider held before it; the filing reports 484,663 shares afterwards. 313 shares at an average of $68.00 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
Does this mean ARWR stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Arrowhead Pharmaceuticals
- SEC Form 4Aug 20, 2026
- SEC Form 4Aug 20, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its ARWR page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
